HC Wainwright set a $75.00 target price on Sarepta Therapeutics (NASDAQ:SRPT) in a research note released on Wednesday, January 3rd. The brokerage currently has a buy rating on the biotechnology company’s stock.
A number of other analysts also recently weighed in on the stock. William Blair reissued an outperform rating on shares of Sarepta Therapeutics in a research report on Monday, October 2nd. Oppenheimer reiterated a buy rating and issued a $76.00 target price on shares of Sarepta Therapeutics in a report on Thursday, September 7th. Nomura reiterated a buy rating and issued a $84.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, September 5th. Needham & Company LLC restated a buy rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, September 6th. Finally, Robert W. Baird restated an outperform rating and set a $101.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 2nd. Two analysts have rated the stock with a sell rating, four have given a hold rating and eighteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $63.88.
Sarepta Therapeutics (SRPT) traded up $2.53 during midday trading on Wednesday, hitting $61.52. 2,217,156 shares of the stock were exchanged, compared to its average volume of 1,700,000. Sarepta Therapeutics has a 12 month low of $26.26 and a 12 month high of $61.89. The firm has a market capitalization of $3,980.00, a P/E ratio of -30.16 and a beta of 1.37. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. The company had revenue of $45.95 million during the quarter, compared to analysts’ expectations of $41.29 million. During the same quarter in the previous year, the business posted ($0.95) earnings per share. sell-side analysts predict that Sarepta Therapeutics will post -3.07 earnings per share for the current fiscal year.
In related news, CEO Douglas S. Ingram acquired 38,138 shares of the stock in a transaction dated Wednesday, November 8th. The stock was acquired at an average cost of $52.44 per share, with a total value of $1,999,956.72. Following the purchase, the chief executive officer now directly owns 420,196 shares of the company’s stock, valued at $22,035,078.24. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the completion of the sale, the director now directly owns 13,333 shares of the company’s stock, valued at $745,181.37. The disclosure for this sale can be found here. Company insiders own 9.60% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Alliancebernstein L.P. increased its holdings in Sarepta Therapeutics by 63.3% during the 2nd quarter. Alliancebernstein L.P. now owns 118,310 shares of the biotechnology company’s stock worth $3,988,000 after purchasing an additional 45,860 shares during the period. 361 Capital LLC purchased a new position in shares of Sarepta Therapeutics in the 3rd quarter valued at $1,914,000. Janney Montgomery Scott LLC purchased a new position in shares of Sarepta Therapeutics in the 3rd quarter valued at $474,000. Oppenheimer & Co. Inc. increased its holdings in shares of Sarepta Therapeutics by 53.0% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 33,592 shares of the biotechnology company’s stock valued at $1,524,000 after acquiring an additional 11,639 shares during the period. Finally, Hikari Power Ltd purchased a new position in shares of Sarepta Therapeutics in the 3rd quarter valued at $1,134,000. 82.02% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/13/hc-wainwright-reiterates-75-00-price-target-for-sarepta-therapeutics-srpt.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.